{"nctId":"NCT01854697","briefTitle":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","startDateStruct":{"date":"2013-03"},"conditions":["Chronic Hepatitis C Infection"],"count":311,"armGroups":[{"label":"Arm A: 3-DAA + RBV in GT1a","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267, ABT-333","Drug: Ribavirin"]},{"label":"Arm B: TPV/PR in GT1a","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ribavirin","Drug: Telaprevir","Drug: Pegylated Interferon alpha 2-a (PegIFN)"]},{"label":"Arm C: 3-DAA + RBV in GT1b","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267, ABT-333","Drug: Ribavirin"]},{"label":"Arm D: 3-DAA in GT1b","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267, ABT-333"]},{"label":"Arm E: TPV/PR in GT1b","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ribavirin","Drug: Telaprevir","Drug: Pegylated Interferon alpha 2-a (PegIFN)"]}],"interventions":[{"name":"ABT-450/r/ABT-267, ABT-333","otherNames":["Viekira Pak","ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ABT-333 also known as dasabuvir","Holkira Pak"]},{"name":"Ribavirin","otherNames":[]},{"name":"Telaprevir","otherNames":[]},{"name":"Pegylated Interferon alpha 2-a (PegIFN)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females between 18 and 65 years, inclusive, at time of Screening\n* Females must be post-menopausal for more than 2 years or surgically sterile or practicing abstinence/specific forms of birth control\n* Subject has never received antiviral treatment for hepatitis C infection\n* Chronic HCV Genotype-1 infection prior to study enrollment\n\nExclusion Criteria:\n\n* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab)\n* Females who are pregnant or plan to become pregnant, or breastfeeding\n* Any current or past clinical evidence of cirrhosis\n* Screening laboratory analyses that showing abnormal laboratory results\n* Use of contraindicated medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV\n* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol\n* Positive screen for drugs or alcohol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"82.4","spread":null},{"groupId":"OG002","value":"98.8","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"78.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)","description":"SF-36V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQoL) covering 2 summary measures: physical component summary (PCS) and MCS; it consists of 8 subscales. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Scoring is done for both MCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"10.59"},{"groupId":"OG001","value":"-5.8","spread":"12.18"},{"groupId":"OG002","value":"-0.3","spread":"8.89"},{"groupId":"OG003","value":"-0.1","spread":"7.73"},{"groupId":"OG004","value":"-6.4","spread":"11.78"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)","description":"SF-36V2 is a generic 36-item questionnaire measuring HRQoL covering 2 summary measures: PCS and MCS; it consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"8.63"},{"groupId":"OG001","value":"-5.5","spread":"8.26"},{"groupId":"OG002","value":"0.4","spread":"5.80"},{"groupId":"OG003","value":"2.2","spread":"4.34"},{"groupId":"OG004","value":"-5.5","spread":"11.46"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 - Secondary Efficacy Analyses","description":"The percentage of participants with sustained virologic response (plasma HCV RNA level \\< LLOQ) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"82.4","spread":null},{"groupId":"OG002","value":"98.8","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"78.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure During Treatment","description":"Participants in Arms A, C or D demonstrating any of the following were considered virologic failures and discontinued therapy:\n\n* Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of \\>1 log10 IU/mL above nadir) at any time point during treatment\n* Failure to achieve HCV RNA \\< LLOQ by Week 6 or\n* Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point after HCV RNA \\< LLOQ during treatment after HCV RNA \\< LLOQ.\n\nParticipants in Arms B and E followed virologic stopping criteria described in the TPV Summary of Product Characteristics; they were considered virologic failures and discontinued therapy as follows:\n\n* HCV RNA \\> 1000 IU/mL at Week 4 to Week 12, discontinue TPV and pegIFN and RBV\n* HCV RNA \\> 1000 IU/mL at Week 12, discontinue pegIFN and RBV\n* Confirmed HCV RNA \\> lower limit of detection (LLOD) at Week 24, discontinue pegIFN and RBV\n* Confirmed HCV RNA \\> LLOD at Week 36, discontinue pegIFN and RBV.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1.2","spread":null},{"groupId":"OG004","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 24 weeks post treatment among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1.2","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)","description":"The percentage of participants with sustained virologic response (plasma HCV RNA level \\< LLOQ) 24 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"82.4","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"78.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["HEADACHE","NAUSEA","PRURITUS","FATIGUE","ANAEMIA"]}}}